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Purpose: Our goal was to investigate the effects of inhibition of transglutaminase 2 (TGase 2) on endotoxin-induced 
uveitis (EIU)
Methods: EIU was induced in female Lewis rats by single footpad injections of 200 μ g of lipopolysaccharide (LPS). 
TGase 2 inhibitors were administered intraperitoneally 30 minutes before and at the time of LPS administration. 
Rats were sacrificed 24 hours after injection, and the effects of the TGase 2 inhibitors were evaluated by the 
number of intraocular inflammatory cells present on histologic sections and by measuring the TGase 2 activity 
and TGase products in the aqueous humor (AqH). TGase 2 substrates were also assayed in AqH from uveitis 
patients. 
Results: Clinical indications of EIU, the number of cells present on histologic sections, and TGase 2 activity in AqH 
increased in a time-dependent manner, peaking 24 hours after LPS injection. Inflammation in EIU was 
significantly reversed by treatment with TGase inhibitors. A 23-kDa cross-linked TGase substrate was identified 
in the AqH from EIU rats and uveitis patients. MALDI-TOF analysis showed that this substrate in uveitis patients 
was human Ig kappa chain C region. 
Conclusions: TGase 2 activity and its catalytic product were increased in the AqH of EIU rats. TGase 2 inhibition 
attenuated the degree of inflammation in EIU. Safe and stable TGase inhibitors may have great potential for the 
treatment of inflammatory uveitis.
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Acute anterior uveitis is an inflammatory disorder that in-
volves the iris and parts of the ciliary body. Endotoxin-induced 
uveitis (EIU), an animal model similar to acute ocular in-
flammation in humans [1], is characterized by breakdown of 
the blood-aqueous barrier, leading to an extravasation of vascular 
fluid protein and massive infiltration of inflammatory cells, 
predominantly neutrophils, macrophages and T lymphocytes, 
into the anterior chamber of the eye [2, 3]. Although cortico-
steroids are effective in reducing inflammation, they are 
associated with a wide range of complications, including cataract, 
increases in intraocular pressure, and increased susceptibility 
to microbial infection, if administered over extended time 
periods [4]. In addition, some patients are resistant to corti- 
costeroids. Conventional steroid-sparing drugs, including 
antimetabolites, alkylating agents, T-cell inhibitors, and anti-
bodies, have provided significant advances in disease control 
[5, 6]. However, these medications may also have serious 
side-effects, requiring regular monitoring of patients.  
Transglutaminase 2 (TGase 2, EC2.3.2.13) is a Ca
2+ 
-dependent enzyme that catalyzes the formation of isopeptide 
linkages between the carboxamide groups of protein-bound 
glutamine residues and the ε-amino groups of protein- 
bound lysine residues [6,  7]. TGase 2 is expressed at low 
levels in many different tissues but is inappropriately ac-
tivated in a variety of pathological conditions, including 
neurodegenerative diseases, atherosclerosis, inflammatory 
diseases, autoimmune diseases, and fibrosis [8]. In many 
inflammatory diseases, including celiac disease, Crohn’s 
disease, and sporadic inclusion-body myositis, increased Korean J Ophthalmol Vol.24, No.1, 2010
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Table 1. Scores of clinical signs in anterior uveitis
Score Slit-lamp examination
0 No deviation from normal
1 Slight iris vessel dilatation. Some A/C cells (less than 10 
per field)
2 Iris hyperemia, some limitation in pupil dilation, freely 
moving A/C cells (10-20 per field) and slight flare.
3 Iris miotic, irregular and hyperemic and sometimes slightly 
damaged. Considerable flare and cells.
4 Seriously damaged and hyperemic iris; mitotic pupil, often 
filled with protein. Cloudy and gel-like aqueous humor. 
TGase activity is closely associated with inflammation [9,  10]. 
Moreover, the inhibition of TGase 2 may reverse the in-
flammatory process in brain injury, allergic conjunctivitis, 
and in a lung fibrosis model [11-13].
We found that TGase 2 expression is dramatically increased 
in an animal model of allergic conjunctivitis and that rationally 
designed TGase inhibitors reversed the inflammatory 
process in this model [14].  The association between increased 
TGase 2 activity and uveitis suggests that TGase 2 expression 
may play a significant role in EIU pathogenesis. We therefore 
assessed whether TGase 2 expression is increased during 
the progression of EIU and if this process can be reversed 
by TGase inhibitors. 
Materials and Methods
Animals and EIU 
Uveitis was induced in 8-10 weeks old female Lewis 
rats weighing 190 g to 210 g by a 200 μg injection of lip-
opolysaccharide (LPS; Salmonella typhimurium; Sigma- 
Aldrich, San Francisco, CA, USA) dissolved in sterile, 
pyrogen-free saline into the foot. Clinical signs of uveitis 
were monitored by direct slit-lamp biomicroscopy of the 
anterior eye segment (Table 1) [15].
Histologic evaluation
Rats were euthanized every 4 hours after LPS injection, 
up to 48 hours. The eyes were enucleated immediately 
and stored in a mixture of 10% formalin and 2.5% glutaraldehyde 
for 24 hours, then embedded in paraffin. Sagittal sections 
(5 μm thick) were cut near the optic nerve head and stained 
with hematoxylin and eosin. The number of infiltrating 
cells was counted on each histologic section of the iris-ciliary 
body. Neutrophils were counted by an investigator unaware 
of the treatment groups. For each animal, the number of 
cells represented the mean count in three serial sections. 
TGase 2 activity in EIU
Aqueous humor (AqH) was collected immediately after 
treatment by anterior chamber puncture (15-20 μL/rat) using 
a 30-gauge needle at 0, 4, 8, 12, 24, 32, 40, and 48 hours 
after LPS injection. TGase activity in AqH was assayed 
by measuring the covalent binding of [1,4-14C] putrescine 
to succinylated casein [6]. Each AqH sample was in-
cubated for 1 hour at 37°C with 0.5 mL reaction mixture 
containing 0.1 M Tris-acetate (pH7.5), 1% (wt/vol) succi-
nylated casein, 1 mM EDTA, 10 mM CaCl2, 0.5% (wt/vol) 
lubrol PX, 5 mM DDT, 0.15 M NaCl and 0.5 mCi of 
[1,4-14C] putrescine dihydrochloride (DuPont-New England 
Nuclear, Boston, MA, USA). The reaction was terminated 
by the addition of 4.5 mL of cold (4°C) 7.5% (wt/vol) 
trichloroacetic acid (TCA). The TCA-insoluble precip-
itates were collected onto GF/A (Millipore, Bedford, MA, 
USA) glass fiber filters, washed with cold 5% (wt/vol) 
TCA, dried and counted. The negative control was TGase 
preincubated with buffer only. 
Western blot analysis (cross linking)
AqH samples were electrophoresed on 10-20% gradient 
SDS gels in Tricine buffer (Invitrogen, Carlsbad, CA, USA) 
and transferred to nitrocellulose filters, which were in-
cubated with 5 μg/mL mouse monoclonal anti-isopeptid 
antibody, followed by 0.1 μg/mL anti-mouse, 814-MAM 
(CovalAb, Lyon, France) secondary antibody. The blots 
were developed by enhanced chemiluminescence (Pierce, 
Milwaukee, WI, USA). 
TGase inhibitors 
The TGase inhibitor, R2 peptide (KVLDGQDP), which 
has been shown to be effective both in vitro and in vivo, 
was synthesized as described previously [5]. Cystamine (CTM), 
which inhibits TGase activity by blocking the access of 
the glutamate residue in substrate proteins from the TGase 
active site, was obtained from Sigma-Aldrich [16]. Thirty 
minutes before and immediately after LPS injection, the 
rats were injected intraperitoneally with R2 (10 mg/kg, 500 
μm), CTM (6.0 mg/kg, 500 μm), or dexamethasone (2 mg 
/kg) in 0.2 mL pyrogen-free saline. Control rats were in-
jected with 0.2 mL pyrogen-free saline 30 min before and 
immediately after LPS injection. AqH samples were col-
lected 24 hours after LPS injection.  
Human AqH
We obtained 200 µL AqH aliquots from human eyes 
with uveitis using 30-gauge needles. All procedures adhered 
to the tenets of the Declaration
 of Helsinki, and local approval 
was received from the Investigational
  Review Board of 
the Asan medical center. Informed consent was obtained 
from each patient
  and control. 
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Fig. 1. Disease activity and increasing transglutaminase 2 (TGase 2) activity over time in endotoxin-induced uveitis (EIU). EIU as induced in 
female Lewis rats by a single foot pad injection of 200 μg lipopolysaccharide (LPS), and disease activity and TGase 2 activity in aqueous humor 
(AqH) were determined every 4 hour after LPS administration. (A) Clinical findings were assessed on a scale of 0 to 4 according to the extent 
of inflammation and tissue damage. Peak inflammation was seen 24 hr after LPS stimulation (mean±SD of 10 eyes).  (B) Cellular infiltration 
over time. Infiltration peaked 24 to 28 hr after LPS stimulation (mean±SD of 10 eyes).  (C) TGase 2 activity over time. TGase activity in-
creased 130-fold 24 hr after LPS stimulation (mean± SD, n=3). (D) Western blotting using a TGase cross-linked antibody, revealing that a 
23-kDa protein increased concomitantly with increases in TGase 2 activity.
Protein samples (10 μg) were diluted in 4X NuPAGE 
LDS sample buffer (Invitrogen), separated by SDS-PAGE 
using 4-12% NuPAGE Bis-Tris Gel (Invitrogen), and vi-
sualized by staining with Coomassie blue. Protein spots 
excised from the gel were washed with 50 mM ammonium 
bicarbonate (ABC) for 10 minutes and with 50 mM ABC/ 
70% acetonitrile for 10 minutes repeatedly until the blue 
color disappeared. Each de-stained gel piece was in-
cubated with 50 μLof 10 mM dithiothreitol at 55
oC for 
20 minutes, washed with 50 mM ABC/70% ACN for 10 
minutes, incubated with 50 μL of 10 mg/mL iodoaceta-
mide in the dark for 20 minutes, and again washed with 
50 mM ABC/70% ACN for 10 minutes. Each gel piece 
was dried and incubated overnight with 10 ng of modi-
fied trypsin (Promega) in 20 μl of 50 mM ABC at 37
oC. 
The supernatant was collected after digestion, and the gel 
piece was extracted with 100 μl of 0.1% trifluoroacetic 
acid (TFA). The extracts were combined, dried in a 
SpeedVac (Labconco, Fort Scott, KS, USA) and resuspended 
in 0.1% TFA for immediate mass spectrometric analysis 
or stored at –20
oC until use.
MALDI-TOF MS analysis
Peptide and fragment masses were determined using 
MALDI-TOF mass spectrometry (4700 Proteomics 
Analyzer; Applied Biosystems, Framingham, MA, USA). 
The matrix of choice was 5 mg/mL-α-cyano-4-hydroxycin-
namic acid (CHCA; Sigma, St. Louis, MO, USA) in 0.1% 
aqueous TFA/ACN (1:1, v/v). The samples were desalted 
using Zip-Tips C18 (Millipore), eluted in matrix solution 
directly on the target, then air-dried. The analyses were 
performed in positive ion reflectron mode, and spectra 
were calibrated at 50 ppm tolerance using the [M+H] ion 
from 4700 Cal Mix (Applied Biosystems); des-Arg
1-bradykinin 
(Mr 904.4681), angiotensin 1 (Mr 1296.6853), Glu-fi-
brinopeptide B (Mr 1570.6774), ACTH 1–17 clip (Mr 
2093.0867), ACTH 18–39 clip (Mr 2465.1989), and ACTH 
7–38 clip (Mr 3657.9294). For MS/MS experiments, the 
collision energy, which is defined by the potential difference 
between the source acceleration voltage (8 kV) and the 
floating collision cell (7 kV), was set at 1 kV, and calibra-
tion was performed at 0.1 Da tolerance with Glu-fibrinopep-
tide B peptide. Inside the collision cell, the selected ions 
collided with air at a pressure of 2×10
-6 Torr. The 
MS/MS spectra of selected ions were the summation of 
30 sub-spectra, each acquired with 50 laser pulses. Data 
analysis and MS/MS database searching was performed 
using Data Explorer (Applied Biosystems, Foster, CA, 
USA) and MASCOT (Matrix Science Ltd., London, UK).
Results
TGase 2 activity in EIU
When we assayed the time course of EIU, we found Korean J Ophthalmol Vol.24, No.1, 2010
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Fig. 2. Effect of transglutaminase (TGase) inhibitors on disease activity and TGase 2 activity in Endotoxin-induced uveitis Rats were injected 
intraperitoneally with R2 peptide (KVLDGQDP,10 mg/kg, 500 μm), cystamine (CTM, 6.0 mg/kg, 500 μm) or dexamethasone (2 mg/kg) 30 
minutes before and at the time of lipopolysaccharide administration. Disease activity and TGase 2 activity in aqueous humor were determined 
24 hr later. (A) Grading of inflammation, showing a two-fold reduction in the R2-treated rats (mean±SD of 6-8 eyes). (B) Number of infiltrat-
ing cells on histologic sections, showing a three-fold reduction in the R2-treated group (mean±SD of 6-8 eyes). (C) TGase 2 activity, showing 
a ten-fold reduction in the R2 treated rats (mean±SD of 6-8 eyes). 
*Significantly different from control. p<0.001 by unpaired Student t-test.
that the peak of inflammation, as shown by biomicroscopy, 
was detected 24 hours after LPS stimulation (Fig. 1A). At 
this time, hyperemic irises and miotic pupils with or with-
out hypopyon were prominent. The numbers of inflammatory 
cells on the histologic sections were significantly increased 
at 24 and 30 hours after LPS stimulation and decreased 
thereafter (Fig. 1B). Total TGase 2 activity in the AqH 
was increased at 24 and 30 hours after LPS stimulation 
(Fig. 1C), in parallel with the severity of inflammation. 
TGase 2 substrates in EIU
To test whether TGase 2 substrates were present in the 
AqH in EIU, we used Western blotting to assay for TGase 
catalytic products. Using antibodies crosslinked to TGase, 
we detected a 23 kDa protein (Fig. 1D), the amount of 
which increased concomitantly with the increase in 
TGase 2 activity (Fig. 1C).
Effect of TGase inhibitors in EIU
Severe inflammation was observed in the anterior seg-
ment of the eyes of rats with EIU 24 hours after LPS 
administration. Treatment with the TGase inhibitor R2 
(KVLDGQDP) reduced inflammation two-fold (Fig. 2A), 
as well as reducing the number of infiltrating cells on 
histologic sections by three-fold (Fig. 2B). In contrast, 
CTM did not show anti-inflammatory effects on EIU 
(Fig. 2C).
Identification of TGase 2 substrate
In addition to the finding that a 23 kDa protein bound 
by anti-TGase 2 antibodies in AqH increased significantly 
at 24 and 30 hours after LPS injection but decreased 
thereafter, we observed increased amounts of a 23 kDa 
cross-linked molecule in human AqH from eyes with 
uveitis (Fig. 3A). To identify the protein, this band was 
subjected to MALDI-TOF analysis. We found that this 
band was compatible with the human (P01834) Ig kappa 
chain C region (Fig. 3B-3E). 
Discussion
We showed that increased total TGase 2 activity in 
EIU correlates with clinical findings and with increases in 
inflammatory cell numbers. These results were not sur-
prising because TGase 2 has been shown to be a marker 
of inflammation [17]. However, our finding that TGase 2 
activity corresponded to the degree of inflammation in 
EIU in a time-dependent manner suggests that TGase 2 
may play a key role in the inflammatory process in EIU. 
TGase 2 expression has been shown to increase in other in-
flammatory diseases, including inflammatory myositis, LPS- 
induced inflammation, and celiac disease [10,  12,  15,  16]. 
Moreover, TGase 2 was recently reported to activate NF-kB, 
which is responsible for the generation of the proinflammatory 
mediators nitric oxide and TNF-α [13,  17]. Increased expression 
of TGase 2 may exacerbate inflammation by amplifying 
NF-kB activation through I-kBa depletion. Furthermore, 
TGase 2 inhibition reduced nitric oxide generation during 
LPS-induced inflammation [13,  18].
When we tested the effects of R2, a peptide inhibitor 
of TGase, on inflammation in EIU, we found that this in-
hibitor reduced inflammation, although to a smaller extent 
than what has been seen with steroids. In contrast, CTM 
did not have beneficial anti-inflammatory effects, possibly 
due to its poor ocular permeability. The ability of R2 to 
gain access to the eye may also be limited owing to its 
pure octapeptide structure, which may result in its anti-in-
flammatory effect being lesser than that of steroids [19,  20]. 
Efforts are needed to develop safe, specific inhibitors of JH Sohn, et al. Therapeutic Target of Transglutaminase 2 Inhibitor
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Fig. 3. MS/MS identification of transglutaminase 2 (TGase 2) substrate in Aqueous humor (AqH) from uveitis patients. 
(A) AqH samples from the eyes of human patients with uveitis were obtained using a 30-gauge needle. Protein samples (10 g) were resolved 
in 4-12% gels and stained with Coomassie blue. The indicated bands were excised for in-gel tryptic digestion. (B) MS/MS spectra of 1797.9 
peptide. (C) MS/MS spectra of 1946.1 peptide. (D) MS/MS spectra of 1876.0 peptide. (E) Amino acid sequence of Ig chain C region. The 
identified peptides are indicated in bold.
TGase 2 that are able to effectively permeate the eye. Also, 
the anti-inflammatory effect of TGase inhibitors was 
maintained while there was active inflammation on EIU 
(data not shown), but as the LPS-induced inflammatory 
response in EIU is naturally diminished after 48 hours, 
we were unable to determine the duration of the anti-in-
flammatory effect of the TGase inhibitors.
We found that a 23 kDa cross-linked molecule in AqH 
increased in concentration in parallel with TGase 2 activ-
ity and the inflammatory process in EIU. Interestingly, 
increased quantities of a protein band of the same size 
were also observed in human AqH from uveitis patients. 
MALDI-TOF analysis of this molecule showed that it is 
a human (P01834) Ig kappa chain C region, suggesting 
that TGase 2 may aggregate with Ig kappa chains, and 
that these aggregated molecules may play a role in in-
flammatory uveitis. Plasma cells usually produce excess 
amounts of light chains relative to heavy chains and secrete 
free light chains [21].
  Under normal circumstances this 
does not pose a problem, however occasionally free mon-
oclonal light chains aggregate in various pathological 
forms. Severe light chain aggregation has been observed 
in light chain amyloidosis as well as in light chain deposition 
disease. The Km allele of Ig is frequently associated with 
A B
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anterior uveitis, and immune complexes have been de-
tected in the AqH of eyes with endogenous uveitis [21]. 
Our results suggest that light chain structures may be 
changed by cross-linking to TGase 2, and that this change 
may lead to the inflammatory responses seen in EIU. 
In summary, we demonstrated that TGase 2 is actively 
involved in the inflammatory process of EIU, and that 
this process was effectively reversed by the TGase2 in-
hibitor, R2. TGase 2 may be a potential novel therapeutic 
target in autoimmune uveitis. 
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